^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
homoharringtonine derivative (BS-HH-002.SA)
i
Other names: BS-HH-002.SA , HH-002, BS-HH-002, BS HH 002.SA, HH-002.SA
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Bensheng Pharma
Drug class:
JAK2 inhibitor, Apoptosis stimulant, MCL1 inhibitor, STAT3 inhibitor, STAT5 inhibitor, Signal transduction pathway inhibitor
Related drugs:
3years
Therapeutic effects of an innovative BS-HH-002 drug on pancreatic cancer cells via induction of complete MCL-1 degradation. (PubMed, Transl Oncol)
BS-HH-002 is a newly developed drug with excellent antitumor activity, which resulted from the modification and optimization of the side structure of the homoharringtonine (HHT). Compared to HHT, BS-HH-002 quickly reached high blood concentration after intravenous injection or oral administration, without causing obvious cardiac toxicity. These results indicate that BS-HH-002 is a promising new anti-cancer drug to treat pancreatic and other solid tumors.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1)
|
Synribo (omacetaxine mepesuccinate) • homoharringtonine derivative (BS-HH-002.SA)
Share via
